Details for Patent: 9,844,510

Which drugs does patent 9,844,510 protect, and when does it expire?

Patent 9,844,510 protects ELLA and is included in one NDA.

This patent has thirty-five patent family members in twenty-seven countries.

Summary for Patent: 9,844,510

Patent landscape, scope, and claims:

Title:	Ulipristal acetate tablets
Abstract:	The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.
Inventor(s):	Gainer; Erin (Paris, FR), Guillard; Helene (Paris, FR), Gicquel; Denis (Orgeval, FR), Henrion; Marianne (Paris, FR), Gnakamene; Celine (Paris, FR)
Assignee:	Laboratoire HRA-Pharma (Paris, FR)
Application Number:	15/185,508
Patent Claim Types: see list of patent claims	Use; Formulation; Device; Dosage form;

Drugs Protected by US Patent 9,844,510

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Lab Hra Pharma	ELLA	ulipristal acetate	TABLET;ORAL	022474-001	Aug 13, 2010	AB	RX	Yes	Yes	9,844,510		Y

International Family Members for US Patent 9,844,510

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009326084
Brazil	PI0922796
Canada	2745084
China	102245173
China	105267168